球形胶质tau蛋白病与额颞叶痴呆的关联:胶质细胞疾病谱的扩展
本文综述了PubMed上88例已发表的球形胶质tau蛋白病(GGT)病例的临床、人口学、神经病理和遗传数据,探讨GGT与额颞叶痴呆及相关疾病的关联。GGT占tau病理型额颞叶变性不足10%,其神经元与非神经元病理的罕见组合增加了诊断难度。综述提示胶质tau病理的区域分布与神经元变性相关,需提高临床和研究中对GGT的认识。
要点
- GGT患者中50.0%为特发性,23.9%存在MAPT基因变异。
- 特发性GGT起病年龄70(8)岁,MAPT变异者54(9)岁。
- 最常见临床特征为原发性进行性失语(25.0%)和行为变异型额颞叶痴呆(22.7%)。
核心结论
- 综述已发表数据提示胶质tau病理的区域分布与神经元变性之间存在关联。
- 针对胶质tau积累或维持其神经元支持功能可能需要不同的治疗或神经保护策略。
研究设计与样本
- 本综述通过PubMed检索并汇总了88例已发表的GGT病例的临床、人口学、神经病理和遗传数据。
主要发现
- 88例GGT患者中女性46例(52.3%),平均(SD)起病年龄65(11)岁。
- 特发性GGT与MAPT变异者相比,平均(SD)症状起始年龄为70(8)岁 vs 54(9)岁,平均(SD)疾病持续时间为7(3)年 vs 6(3)年。
- 女性患者症状起始年龄通常比男性患者大6岁(平均[SD]年龄,68[11]岁 vs 62[11]岁)。
- 最常见的主要临床特征为原发性进行性失语(22例[25.0%])、行为变异型额颞叶痴呆(20例[22.7%])、上运动神经元体征(11例[12.5%])、记忆障碍(7例[8.0%])和Richardson综合征(7例[8.0%])。
- 仅7例(8.0%)存在共病蛋白病。
关键数值与推荐
- GGT占tau病理型额颞叶变性病例不足10%。
- 2013年共识研究将GGT分为三种神经病理亚型(I-III型),以少突胶质细胞和/或星形胶质细胞中磷酸化tau免疫阳性包涵体为特征。
- II型主要局限于皮质脊髓系统。
临床怎么用
- 临床预测GGT亚型的价值低,对神经病理亚型划分的必要性提出质疑。
- 需提高临床和研究中对GGT的认识,并开发更准确的临床前模型以探索疾病机制和追踪进展。
局限性
- GGT发病率低,且神经元与非神经元病理的罕见组合阻碍了识别和准确诊断。
- 需进一步神经病理研究明确II型GGT应解释为非典型进行性核上性麻痹还是独立实体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Globular glial tauopathies (GGTs), as defined by a consensus study in 2013, belong to the group of frontotemporal lobar degenerations and expand the spectrum of glial-predominant neurodegenerative diseases. Three neuropathological subtypes of GGT (types I-III) are characterized by phosphorylated tau-immunopositive inclusions that are predominantly in oligodendroglia and/or astroglia in the frontal, temporal, and/or precentral cortices. Type II is largely restricted to the corticospinal system. The low incidence of GGT (<10% of cases of frontotemporal lobar degeneration with tau pathology), together with its unusual combination of neuronal and nonneuronal pathology, has hindered identification and accurate diagnosis. This review collated clinical, demographic, neuropathological, and genetic data from 88 published GGT cases identified on PubMed to examine the association between GGT and frontotemporal dementia and associated disorders. OBSERVATIONS: Among 88 patients with GGT (46 female [52.3%]; mean [SD] age at disease onset, 65 [11] years), 44 patients (50.0%) had idiopathic disease, and 21 patients (23.9%) had a variation in the microtubule-associated protein tau (MAPT) gene. Those with idiopathic GGT compared with those with a variation in MAPT had a mean (SD) age at symptom onset of 70 (8) years vs 54 (9) years and a mean (SD) disease duration of 7 (3) years vs 6 (3) years, respectively. A similar sex distribution was observed among patients with GGT; however, female patients were typically 6 years older at symptom onset than male patients (mean [SD] age, 68 [11] years vs 62 [11] years, respectively). Disease duration was similar in both sexes (mean [SD], 6 [3] years for women and 6 [4] years for men). The most common predominant clinical features were primary progressive aphasia (22 patients [25.0%]), behavioral-variant frontotemporal dementia (20 patients [22.7%]), upper motor neuron signs (11 patients [12.5%]), memory impairment (7 patients [8.0%]), and Richardson syndrome (7 patients [8.0%]). Although some demographic differences between GGT subtypes were identified, the predictive value of the clinical presentation was low, calling into question the need for neuropathological subtyping. Further neuropathological studies are needed to clarify whether GGT type II should be interpreted as atypical progressive supranuclear palsy or a separate entity. Few cases (7 patients [8.0%]) had coexisting proteinopathies. CONCLUSIONS AND RELEVANCE: This review of the published data suggests an association between regional distribution of glial tau pathology and neuronal degeneration. Targeting glial tau accumulation or sustaining their neuron-supportive function might require different therapeutic or neuroprotective strategies and more accurate preclinical models to explore disease mechanisms and track progression. Emerging data support the important role of glia in the pathogenesis of neurodegenerative disorders, highlighting the need to raise awareness of GGT in clinical and research settings.
引用
- Forrest SL, Kril JJ, Kovacs GG, et al. Association Between Globular Glial Tauopathies and Frontotemporal Dementia-Expanding the Spectrum of Gliocentric Disorders: A Review. JAMA Neurol. 2021. PMID: 34152367. doi:10.1001/jamaneurol.2021.1813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。